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Abstract
Due to the morbidity of mothers and newborns caused by fetal growth restriction (FGR) and 
preeclampsia, preventive measures should be taken, especially in women at high risk of developing 
these conditions. Many studies have been conducted on the prevention of FGR and preeclamp-
sia in high-risk women, especially anticoagulants, aspirin, paravastatin, nitric oxide, microele-
ments (L-arginine, folic acid, vitamins E and C, phytonutrients, vitamin D) and calcium.
The aim is to improve perinatal consequences by preventing FGR in high-risk women. 
Materials and methods: A prospective study of 137 pregnant women in the period of 
110–136 weeks was conducted at the Perinatal Center in Kyiv. Pregnant women were divided into 
3 groups. The main group included 47 women at high risk of FGR who received therapy (low doses 
of aspirin, low molecular weight heparin (LMWH) and vitamin and micro elements drugs). The 
comparison group included 45 women who had a high risk of FGR but did not receive treatment. 
The control group consisted of 45 women who were not at risk of FGR. The frequency of FGR and 
placental dysfunction were analyzed as well as a fetal distress was analyzed ante- and intranatally.
Results: Therapy with low doses of aspirin, LMWH and a complex preparation of vitamins 
and micro elements improves the course of pregnancy and gestational complications. In the main 
group FGR was detected in 8.5 %, in the comparison group – in 17.8 %, in the control group – 4.4 %. 
Placental dysfunction was detected in 13.3 % in the control group, and only 6.4 % in the main 
group that was close to the control group – 2.2 %. Similar tendencies were found for fetal distress 
ante- and intranatally. 
Conclusions: The proposed prophylactic measures can improve maternal outcomes by re-
ducing the level of gestational complications in pregnant women with biochemical signs of risk of 
FGR development. In addition, these preventive measures can reduce the frequency of children 
births with growth restriction, which significantly reduces early neonatal and perinatal morbidity 
and mortality.
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Fetal growth restriction involves conditions under which the fetus does not reach its full 
growth potential. FGR is difficult to determine and measure, so small for gestational age (SGA) 
fetus, determined by centile weight, is often used as the most reliable marker. FGR and SGA can 
be caused by fetal problems such as chromosomal abnormalities, genetic syndromes and fetal in-
fections; maternal disease; environmental toxins. The most common cause of FGR and SGA is 
placental insufficiency. The study focuses on options for FGR prevention, which are closely related 
to the development of placental insufficiency and preeclampsia.
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Prescribing aspirin to prevent FGR, as shown by a recent meta-analysis of large-scale 
studies and a meta-analysis of individual patient data, significantly reduces fetal malnutrition (FM) 
in high-risk mothers (relative risk, 0.9–0.95 % confidence interval, 0.81–1.00). Aspirin in do-
ses > 100 mg starting at 16 weeks of pregnancy or earlier should be recommended. These results 
are supported by the recommendations of national practical guidelines. Aspirin has a number of 
effects at the vascular level that can prevent the development of FGR (Fig. 1). For many years, 
it has been clear that aspirin inhibits the production of prostaglandins and thromboxane by irre-
versible inactivation of the enzyme cyclooxygenase. Thromboxane is a potent vasoconstrictor and 
prothrombotic antiplatelet agent. Prolonged intake of low doses of aspirin irreversibly blocks the 
formation of thromboxane A2 in platelets, inhibiting their aggregation. Recently, researchers have 
drawn attention to new cytoprotective and antioxidant mechanisms of aspirin that are independent 
of cyclooxygenase inhibition. Aspirin acetylates endothelial nitric oxide synthase, which leads to 
the release of nitric oxide from the vascular endothelium [1]. In addition, aspirin increases the 
activity of hemoxygenase-1 in endothelial cells to catabolize heme, which leads to a decrease in 
oxidative stress, damage and inflammation [2]. Most aspirin studies have focused on the treatment 
of preeclampsia as the primary outcome, with FGR therapy included only as a secondary outcome. 
However, the volume and quality of the obtained evidence allows to interpret and to implement 
these research results in a meaningful way. In 2018, systematic reviews based on a meta-analysis 
at the research level [3] and a meta-analysis of individual patient data [4] from randomized trials 
of aspirin and other antiplatelet agents were published simultaneously, including 20,909 and 
32,217 women, respectively. Both analyzes confirmed the available evidence that aspirin provides 
a slight reduction in the risk of FGR and GP (less than 5 or less than the 10th percentile) at birth (ana-
lysis of individual patient data, relative risk, 0.9–0.95 % confidence interval [CI] 0, 81–1.00). 
Fig. 1 Pathogenetic mechanisms of placental dysfunction
The results of in vitro and in vivo studies suggest that the administration of low molecu-
lar weight heparin may prevent FGR; however, the evidence from randomized controlled trials is 
conflicting. Unfractionated heparin (UFH) and low molecular weight heparin (LMWH) during 
pregnancy are commonly used for thromboprophylaxis and treatment of venous thromboembo-
lism. Recently, LMWH has been preferred to UFH, which is a safe and effective drug for these 
indications [5]. Initial interest in the use of heparins for the prevention of placental pathologies 
was focused on their anticoagulant properties and the presumed ability to prevent thrombosis and 
subsequent placental infarction, which leads to miscarriage. In vitro and in vivo data suggest that 
heparins have various additional biological properties, including anti-inflammatory [6], comple-
ment inhibition [7], and antitumor [8], and are pro-angiogenic (Fig. 1). These additional effects 








for the prevention of placental-mediated pregnancy complications, including FGR. A meta-analy-
sis of multicenter studies does not show any positive prophylactic effect of low molecular weight 
heparin on the primary rate of placental-mediated complications, including FGR (95 % confidence 
interval) [9]. Thus, low molecular weight heparin will be prescribed only in the conditions of this 
study, as one of the drugs for the combined prevention of FGR. 
One of the pathogenetic links in the development of placental dysfunction is micronutrient 
deficiency, so the option to prevent gestational complications is to prescribe a complex drug con-
taining 5 carefully selected components for a pregnant woman. This drug contains fish oil (doxa-
hexaenoic acid) in a dose of 200 mg, folic acid (vitamin B9) – 400 µg, cholecalciferol (vitamin P3) – 
5 µg, natural vitamin E (a-tocopherol) – 12 mg, potassium iodide – 150 µg.
Scientists are now looking forward to obtaining the results of randomized controlled clinical 
trials with sildenafil therapy [10] in predicting fetal growth restriction with early onset. Another 
approach is to focus on improving uteroplacental circulation with new therapeutic drugs. One of 
the most advanced methods is gene therapy using endothelial factor of uterine vascular growth, 
which is introduced into clinical practice by gene therapy specialists [11]. 
Other approaches using targeted therapy include the use of nanoparticles and miRNAs for 
local delivery of drugs to the endothelium of the uterine arteries or trophoblast [12].
The aim of this study was to evaluate the complex prophylactic therapy of pregnant women 
with existing risk factors for FGR in the first trimester, namely a decrease in PAPP-A, an increase 
in MPV and an increase in pulsation index and resistance index in uterine arteries.
2. Materials and methods
The prospective study was conducted on the basis of a specialized women’s clinic of the 
Kyiv Perinatal Center during 2018–2020. The study included patients who were registered in 
a specialized women’s clinic during gestation 110 – 136 weeks. The pregnancy was observed in 
a specialized women’s clinic, and further delivery was performed at the Kyiv Perinatal Center. 
Pregnant women were divided into 3 groups. The formation of the groups was based on the ul-
trasound and laboratory signs of high risk of fetal growth restriction detected during the first 
combined screening – PAPP value less than 0.5 IU, increase in mean platelet volume over 10 fl, 
increase in pulsation index of uterine arteries over 1.34 and resistance index over 0.65. The main 
group included 47 pregnant women with two or more of the above criteria for high risk of fetal 
growth restriction, who from the moment of inclusion in the study were prescribed a set of preven-
tive measures: aspirin at a dose of 75 µg per day, low molecular weight heparin at a prophylactic 
dose, specified by the manufacturer and complex drug of vitamins and microelements. The com-
parison group included 45 pregnant women in whom risk criteria for fetal growth restriction were 
identified in the first trimester, but they did not receive preventive treatment. The control group 
consisted of 45 women without risk factors for fetal growth restriction during the examination 
in the first trimester. The study did not include patients with multiple pregnancies and a high risk 
of genetic abnormalities.
The study at the planning stage passed the examination of the bioethics committee of the 
National University of Health named after P. L. Shupyk No. 8 from 23.10.2017. All pregnant women 
who participated in the study were offered informed consent, which contained a description of the 
study, the potential benefits and harms of participating in and refusing to participate in the study. 
After signing the consent, a copy was provided to the patient. The examination states that the de-
sign of the study complies with the Helsinki Declaration.
Groups of pregnant women were suitable for comparison by age and parity. The aver-
age age of pregnant women in the main group was 25.5 ± 3.3 years, in the comparison group – 
26.5 ± 3.4 years, in the control group – 27.3 ± 3.1 (p ˂ 0.05). In all groups, women giving birth for the 
first time predominated – 72.3 % in the main group, 66.7 % – in the control group, 71.1 % – in the 
comparison group (p ˂ 0.05).
During the observation, patients underwent ultrasound monitoring at the scheduled time – 
at 20–21 weeks and at 32–34 weeks. In addition, at each visit to the women’s clinic the height of the 
uterine fundus was measured. At a decrease in growth from 2 cm / week, ultrasound fetometry with 
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dopplerometry was repeated out of plan. In the dynamics of observation the frequency of diagnosis 
of fetal growth restriction (estimated mass less than the 10th percentile), uteroplacental circula-
tion (slow blood flow in the umbilical artery), fetal distress before labor (zero or reverse blood 
flow in the umbilical artery, assessment of the umbilical artery, fetal profile 5 points or less) and 
fetal distress in childbirth (abnormal CTG assessment by NICE criteria) were analyzed Differenc-
es in the frequency of these complications in childbirth were assessed using Student’s test [13]. 
The statistical probability was indicated by the value of p > 0.05. The relative proportions of the 
indicators by groups were estimated using alternative analysis with the Fisher angular transforma-
tion criterion.
For each of the analyzed gestational complications, the relative risk of development was 
calculated (compared with the control group).
3. Research results




Gestational complication Main group (n = 47) Comparison group (n = 45) Control group (n = 45)
Fetal growth restriction, abs. (%) 4 (8.5)*# 8 (17.8)* 2 (4.4)
Fetal growth restriction up to 30 weeks, abs. (%) 1 (2.1)# 4 (8.9)* 1 (2.2)
Placental dysfunction, abs. (%) 3 (6.4)*# 6 (13.3)* 1 (2.2) 
Fetal distress before labor, abs. (%) 4 (8.5)* 5 (11.1)* 1 (2.2)
Fetal distress before labor up to 36 weeks,abs. (%) 1 (2.1)# 4 (8.9)* –
Fetal distress in childbirth, abs. (%) 5 (10.6)# 11 (24.4)* 3 (6.7)
Note: * – р ≤ 0.05 when compared with the control group; # – р ≤ 0.05 when compared with the comparison group
Since the main objective of the study was to prevent fetal growth restriction, the differences 
between groups in the frequency of this complication were analyzed first of all. The incidence of 
this complication was significantly higher among women who had a high risk of fetal growth re-
striction in the first trimester and did not receive the proposed treatment than in the control group 
and equaled 17.8 % vs. 4.4 % (relative risk – 4.0, confidence interval 95 %). Instead, the appoint-
ment of the proposed complex, although did not allow to achieve the level of the control group, but 
significantly reduced the frequency of fetal growth restriction in the main group to 8.5 % vs. 17.8 % 
in the comparison group (relative risk 1.9, confidence interval – 95 %). 
The difference is more pronounced if we take into account the early detection of fetal growth 
restriction – up to 30 weeks. If in the comparison group 8.9 % of pregnant women had the deve-
lopment of this complication up to 30 weeks (relative risk 4.0, confidence interval 95 %), the main 
group on this indicator approached the level of the control group (relative risk 0.957, confidence 
interval 95 %). It is the early onset of fetal growth restriction that is more significant for perinatal 
mortality and neonatal morbidity, as it often leads to the need for critical premature birth and the 
birth of a child with extremely low body weight. 
Placental disorders in the form of slowing of blood flow in the umbilical artery were more 
common in women with identified risk factors (13.3 % in the comparison group vs. 2.2 % in the 
control group, relative risk 6.0, CI 95 %). In contrast to it, the use of the proposed treatment in 
women with high risk led to a decrease in this indicator to 6.4 % (relative risk 2.8, CI 95 %).
Fetal distress before childbirth was registered in 5 women (11.1 %) from the high-risk group, 
which significantly exceeds the control group (relative risk 5.0, CI 95 %). In 4 of 5 women in the 
comparison group, distress was registered before the onset of gestational maturity of the fetus. 
In the main group, despite the presence of these risk factors, the use of treatment reduced the over-
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all incidence of fetal distress before childbirth (relative risk 3.8, CI 95 %), the maximum was in 
premature pregnancy up to 2.1 %.
The prescription of a therapeutic complex of drugs has significantly reduced the frequency 
of fetal distress in childbirth.
4. Discussion
The obtained data indicate that the detection of the risk of fetal growth restriction in the first 
trimester is not only theoretical but also practical. Since the violation of placental circulation is 
based on endothelial dysfunction, the appointment of a set of measures to compensate for it – from 
achieving a favorable ratio of prostacyclin / thromboxane, prevention of excessive activation of the 
hemostasis system to rational supplementation with micro elements and vitamins has a prophylac-
tic effect. 
In most national and international guidelines, the recommended dose of aspirin for the pre-
vention of FGR and fetal malnutrition (FM) in high-risk pregnancies is 100–150 mg [14]. However, 
the criteria for selecting patients and accurately identifying the risk group for FGR are unclear be-
cause, as in most studies of therapy to prevent placental-mediated pregnancy complications, studies 
have focused more on the treatment of preeclampsia than FGR treatment. This is underscored by the 
results of a recent large multicenter randomized trial of aspirin to prevent the development of pre-
eclampsia in the early stages. In an evidence-based study of aspirin for the prevention of preeclamp-
sia, a complex algorithm was used to identify high-risk women, including maternal factors, mean 
blood pressure, pulsation index in uterine artery dopplerometry, values of maternal serum biomar-
kers (associated with pregnancy maternal plasma protein A and placental growth factor). Although 
aspirin has been associated with a reduced likelihood of preeclampsia in the early stages, FM values 
below the 10th, 5th, or 3rd percentiles have remained unchanged [15]. This suggests the need for 
alternative prognostic models before we can truly assess the effects of aspirin on high-risk groups.
The effect of heparin therapy on uteroplacental circulation is much clearer. In a small 
open-label study of women with gestational hypertension, LMWH treatment resulted in a decrease 
in the uterine artery resistance index [16]. However, longer-term use of LMWH in a randomized 
controlled trial of the effectiveness of LMWH and aspirin against aspirin alone did not reveal dif-
ferences in the resistance index of the uterine arteries at 22–24 weeks, or in the pulsation index of 
the umbilical arteries in their doppler studies at 22–24 weeks. [17].
The initial randomized trials of heparin have specifically focused on populations of women 
with or without thrombophilia because early evidence suggests a relatively strong association 
between hereditary thrombophilia and the development of preeclampsia and FGR [18]. Recent data 
from prospective cohort studies suggest that any association with thrombophilia and placental-me-
diated complications, if any, is only weak [19], so new trials included women regardless of their 
thrombophilia status. In many studies [20], there are various inclusion criteria that identify women 
not only at high risk of FGR and preeclampsia, but also previous pregnancy complications, such as 
habitual miscarriage, and non-placental conditions, such as venous thromboembolism. 
The difference between the proposed study from those listed above is the inclusion of mi-
cronutrients and vitamins in the therapeutic complex. Modern lifestyle and food stereotypes inher-
ent in women (restriction of consumption of certain foods, vegetarianism, etc.) raise the issue of 
micronutrient deficiencies much higher than the dietary approach. In addition, the proposed study 
expanded the approach to assessing the prophylactic effect. Namely, it studied not only the fre-
quency of fetal growth restriction, but other complications associated with endothelial dysfunction, 
including those that occur in childbirth. 
Study limitations. The limitations of this study, in particular the evaluation of its results, 
are the insufficient statistical sample size and lack of randomization.
Prospect for further research. In the future, the elimination of this limitation is possible 
in the case of increasing the number of observations, expanding the scope of the study to a multi-
center, randomized and placebo-controlled. Such an extension could contribute to the creation of 
a national protocol for the management of pregnant women with a high risk of placental dysfunc-
tion detected in the first trimester.
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1. Such complications, including placental dysfunction (13.3 % vs. 2.2 %), fetal distress be-
fore childbirth (11.1 % vs. 2.2 %) and in childbirth (23.4 % vs. 6.7 %), were much more common 
among women with an increased risk of fetal growth restriction detected in the first trimester of 
pregnancy than among healthy pregnant women, which confirms the value of diagnostic criteria 
for placental dysfunction.
2. Prescribing complex therapy consisting of low doses of aspirin, prophylactic doses of low 
molecular weight heparin, complex preparation of vitamins and micro elements from the first tri-
mester of pregnancy to women with identified risk factors can reduce the incidence of fetal growth 
restriction (from 17.8 % without treatment to 8.5 %), placental dysfunction (13, % vs. 6.4 %), fetal 
distress before childbirth (11.1 % vs. 8.5 %), fetal distress in childbirth (23.4 % vs. 10.6 %).
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